NCT01627340已完成4 期
An Open-label Study to Assess the Immunogenicity and Safety of GSK Biologicals' Hepatitis B Vaccine, Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 667
- 试验地点
- 23
- 主要终点
- Number of Subjects Seroprotected for Anti- Hepatitis B Surface Antigen (Anti-HBs) Antibodies
研究概览
简要总结
This study will evaluate the immunogenicity and safety of Engerix™-B (hepatitis B vaccine) when administered as a primary vaccination course at 0, 1 and 6 months in adults with or without type 2 diabetes mellitus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All subjects must satisfy ALL the following criteria at study entry:
- •Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •A male or female subject aged 20 years and above at the time of screening.
- •Written informed consent obtained from the subject at screening.
- •Subjects diagnosed with type 2 diabetes documented within the past five years, according to the criteria specified by the American Diabetes Association or currently taking any form of anti-diabetic intervention documented by the investigator; or control subjects with no diagnosis or documented history of diabetes, and HbA1c less than 6.5%, as determined by laboratory screening tests.
- •Normal renal function defined as estimated glomerular filtration rate (GFR) ≥ 50 mL/min, estimated through the Modification of Diet in Renal Disease (MDRD) or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, as determined by laboratory screening tests.
- •Seronegative for hepatitis B surface antigen (HBsAg), anti-HBs antibodies and antibodies to hepatitis B core antigen (anti HBc), as determined by laboratory screening tests.
- •Female subjects of non-childbearing potential may be enrolled in the study.
- •Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
- •Female subjects of childbearing potential may be enrolled in the study, if the subject:
- •has practiced adequate contraception for 30 days prior to vaccination, and
- •has a negative pregnancy test on the day of screening and at Visit 1, and
- •has agreed to continue adequate contraception during the entire treatment period and for two months after completion of the vaccination series.
排除标准
- •The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:
- •Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
- •Administration of long-acting immune-modifying drugs within 6 months of the study entry or planned administration at any time during the study period.
- •Administration of a vaccine not foreseen by the study protocol starting from 30 days before each dose of vaccine and ending 30 days after each dose, with the exception of the inactivated influenza vaccine which is allowed at any time during the study if administered at a separate site.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a protocol-specified non-investigational product.
- •Any previous complete or incomplete vaccination against hepatitis B since birth.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection, based on medical history and physical examination.
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine, including latex.
- •Advanced heart failure or any other severe clinical condition that significantly reduces the subject's life expectancy.
- •Acute disease and/or fever at the time of enrolment.
- •Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
- •Any history of alcohol or drug abuse in the past 5 years.
研究组 & 干预措施
Diabetes Group
Experimental
Subjects diagnosed with type 2 diabetes within the five year period before study start who received 3 doses of Engerix™-B vaccine (HBV) at 0, 1 and 6 months. The vaccine was administered intramuscularly (IM) into the deltoid region of the non-dominant arm.
干预措施: Engerix™-B vaccine (Biological)
Control Group
Active Comparator
Subjects with no diagnosis or documented history of diabetes who received 3 doses of Engerix™-B (HBV) vaccine at 0, 1 and 6 months. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
干预措施: Engerix™-B vaccine (Biological)
结局指标
主要结局
Number of Subjects Seroprotected for Anti- Hepatitis B Surface Antigen (Anti-HBs) Antibodies
时间窗: At one month after the third dose of primary vaccination (Month 7)
A seroprotected subject was defined as a vaccinated subject with an anti-HBs antibody concentration greater than or equal to (≥) 10 milli-international units per milliliter (mIU/mL).
次要结局
- Number of Subjects Reporting Any Solicited General Symptoms(During the 4-day (Days 0-3) post-vaccination period)
- Anti-HBs Antibody Concentration(At one month after the third dose of primary vaccination (Month 7))
- Number of Subjects Reporting Any Solicited Local Symptoms(During the 4-day (Days 0-3) post-vaccination period)
- Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)(During the 31-day (Days 0-30) post-vaccination period)
- Number of Subjects Reporting Any Serious Adverse Events (SAEs)(During the entire study period (Month 0 - Month 7))
研究者
研究点 (23)
Loading locations...
相似试验
已完成
2 期
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B ParticipantsHepatitis B, ChronicNCT05275023Janssen Research & Development, LLC37
终止
2 期
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus InfectionHepatitis B, ChronicNCT05005507Janssen Research & Development, LLC1
已完成
3 期
Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 GenotypeHepatitis BNCT00697749GlaxoSmithKline230
Unknown
3 期
Efficacy and Safety of Hepatitis B Vaccine in Chronic Kidney Disease PatientsChronic Kidney DiseaseHepatitis BNCT01933412Tel-Aviv Sourasky Medical Center100
已完成
2 期
An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With ReinjectionTherapeutic Treatment of Inhalation AnthraxNCT02016963Human Genome Sciences Inc.20